Independent Review of the 51st Annual EASL

EASL16_Theme_web_Banner_v2.jpg 

EASL16_LAUNCH_OnDemand.jpg

About the Program

Program Overview

The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016). This program consists of four components: (1) CME Internet Symposium: EASL 2016 Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium; (3) Rapid-Fire Review of EASL 2016: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference To Clinic: Reviewing And Applying Data From EASL 2016: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

The CME Internet Symposium: EASL 2016 Review will feature four HCV experts reviewing and discussing key presentations on chronic hepatitis C presented at EASL 2016. The review and discussion will focus on HCV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations; therapies in development; epidemiology; and diagnosis and clinical management of specific patient populations, including HCV/HIV co-infected and cirrhotic patients.

This activity will enable participating health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program can be accessed at www.viraled.com.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EASL 2016 and it is not sanctioned by the organizers of EASL 2016.

Back to Top   

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Learning Objectives

After completing this activity, the participant should be better able to:

  • Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at EASL 2016 

  • Employ the current treatment paradigms for CHC, including the studies and data presented at EASL 2016 to improve patient care

  • Discuss with patients and colleagues the studies and data on newer therapies for CHC presented at EASL 2016 to decide on appropriate planning of therapy for patients with CHC


 

Release Date:  April 25, 2016

Expiration Date:  April 25, 2017

Estimated time to complete this program:  2 hours

Media: Internet

Back to Top

Course Director and Moderator

Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Faculty

Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Fred Poordad, MD
VP, Academic and Clinical Affairs
The Texas Liver Institute
Clinical Professor of Medicine
University of Texas Health Science Center
San Antonio, Texas

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany 

Back to Top  
Back to Top  

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.  

Back to Top

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Nezam Afdhal, MD

  • Consulting Fees: Merck, Gilead, Echosens, GSK, Ligand, Janssen, Riovant, Co-Crystal, Shionogi
  • Research Support: Gilead, Abbvie, BMS
  • Employee/Salary: Spring Bank Pharmaceuticals
  • Other: Director-TRIO Healthcare
  • Stock: Allurion, Gilead, Spring Bank Pharmaceuticals
Fred Poordad, MD
  • Consulting Fees: Abbvie, Achillion, Anadys, Biolex, BI, BMS, Gilead, GSK, Globelmmune, Idenix, Merck, Novartis, Tibotec/Janssen, Theravance, Vertex
  • Fees for Non-CME/CE Services: Gilead, Kadmon, Merck, Onyx/Bayer, Genentech, GSK, Salix, Vertex
  • Research Support: Abbvie, Achillion, Anadys, Biolex, BI, BMS, Genentech, Gilead, GSK, Globelmmune, Idenix, Idera, Intercept, Janssen, Medarex, Medtronic, Merck, Novartis, Santaris, Scynexis, Vertex, ZymoGenetics
Juergen Rockstroh, MD
  • Consulting Fees: Abbott, Abbvie, Bionor, BMS, Cipla, Janssen, Merck, ViiV
  • Fees for Non-CME/CE Services: Abbvie, BMS, Gilead, Janssen, Merck
  • Contracted Research: Gilead
Mark Sulkowski, MD
  • Contracted Research (to JHU): Abbvie, Gilead, Janssen, Merck
  • Consulting Fees: Abbvie, Crystal, Gilead, Janssen, Merck, Trek

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
 
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattucci, PharmD, CHCP and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
 

Instructions for Participation and Credit

There are no fees for participating and receved CME credit for this activity.  During the period, April 25, 2016 through April 25, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 11384.  Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.  Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

 

Disclaimer

 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

Back to Top

 


 

 

 

 

PIM_small

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.

 

 *Greenwich Mean Time


Prepare to print

Share this page:

Get link code to this page                     


Back to Top